Literature DB >> 11237863

Cyclosporin A reduces canalicular membrane fluidity and regulates transporter function in rats.

S Yasumiba1, S Tazuma, H Ochi, K Chayama, G Kajiyama.   

Abstract

Changes of the biliary canalicular membrane lipid content can affect membrane fluidity and biliary lipid secretion in rats. The immunosuppressant cyclosporin A is known to cause intrahepatic cholestasis. This study investigated whether cyclosporin A influenced canalicular membrane fluidity by altering membrane phospholipids or transporter expression. In male Sprague-Dawley rats, a bile-duct cannula was inserted to collect bile, and sodium taurocholate was infused (100 nmol/min per 100 g) for 60 min. During steady-state taurocholate infusion, cyclosporin A (20 mg/kg) or vehicle was injected intravenously and then bile was collected for 80 min. After killing the rats, canalicular membrane vesicles were prepared. Expression of canalicular membrane transporters was assessed by Western blotting and canalicular membrane vesicle fluidity was estimated by fluorescence polarization. Cyclosporin A reduced biliary lipid secretion along with a disproportionate reduction of lipids relative to bile acids. Cyclosporin A significantly decreased canalicular membrane fluidity along with an increase of the cholesterol/phospholipid molar ratio. Only expression of the transporter P-glycoprotein was increased by cyclosporin A. Because canalicular membrane transporter expression was largely unchanged by cyclosporin A despite a marked decrease of biliary lipid secretion, transporter activity may partly depend upon canalicular membrane fluidity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11237863      PMCID: PMC1221690          DOI: 10.1042/0264-6021:3540591

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  47 in total

1.  19F nuclear magnetic resonance studies of cyclosporine and model unilamellar vesicles: where does the drug sit within the membrane?

Authors:  L Rossaro; S R Dowd; C Ho; D H Van Thiel
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

Review 2.  Metabolism of cyclosporine.

Authors:  G Maurer
Journal:  Transplant Proc       Date:  1985-08       Impact factor: 1.066

3.  Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane.

Authors:  M Böhme; M Büchler; M Müller; D Keppler
Journal:  FEBS Lett       Date:  1993-10-25       Impact factor: 4.124

4.  Cyclosporine-induced interference with uptake of bile acids by human hepatocytes.

Authors:  S A Azer; N H Stacey
Journal:  Transplant Proc       Date:  1993-10       Impact factor: 1.066

5.  Diminution of an acute cyclosporin-induced cholestasis by tauroursodeoxycholate in the rat.

Authors:  P E Queneau; P Bertault-Perès; E Mesdjian; A Durand; J C Montet
Journal:  Transplantation       Date:  1993-09       Impact factor: 4.939

6.  Effect of cyclosporine on bile secretion in rats.

Authors:  F S Rotolo; G D Branum; B A Bowers; W C Meyers
Journal:  Am J Surg       Date:  1986-01       Impact factor: 2.565

7.  The effect of changes in the fluid state of rat liver plasma membrane on the transport of taurocholate.

Authors:  P R Mills; P J Meier; D J Smith; N Ballatori; J L Boyer; E R Gordon
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

8.  Differential effects of cyclosporin A on the transport of bile acids by human hepatocytes.

Authors:  S A Azer; N H Stacey
Journal:  Biochem Pharmacol       Date:  1993-09-01       Impact factor: 5.858

9.  Influence of cyclosporin A treatment on intracellular membranes of hepatocytes.

Authors:  L Bäckman; E L Appelkvist; U Brunk; G Dallner
Journal:  Exp Mol Pathol       Date:  1986-08       Impact factor: 3.362

10.  Influence of cyclosporine A on protein synthesis in rat liver.

Authors:  L Bäckman; E L Appelkvist; G Dallner
Journal:  Exp Mol Pathol       Date:  1988-08       Impact factor: 3.362

View more
  8 in total

Review 1.  Drug-induced cholestasis.

Authors:  Manmeet S Padda; Mayra Sanchez; Abbasi J Akhtar; James L Boyer
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

2.  Bile-salt hydrophobicity is a key factor regulating rat liver plasma-membrane communication: relation to bilayer structure, fluidity and transporter expression and function.

Authors:  Y Asamoto; S Tazuma; H Ochi; K Chayama; H Suzuki
Journal:  Biochem J       Date:  2001-11-01       Impact factor: 3.857

Review 3.  Role and Regulation of Hepatobiliary ATP-Binding Cassette Transporters during Chemical-Induced Liver Injury.

Authors:  Carolina I Ghanem; Jose E Manautou
Journal:  Drug Metab Dispos       Date:  2022-08-01       Impact factor: 3.579

Review 4.  Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions.

Authors:  Li Xing; Yiding Hu; Yurong Lai
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

5.  Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?

Authors:  Jason R Slizgi; Yang Lu; Kenneth R Brouwer; Robert L St Claire; Kimberly M Freeman; Maxwell Pan; William J Brock; Kim L R Brouwer
Journal:  Toxicol Sci       Date:  2015-10-26       Impact factor: 4.849

Review 6.  Rodent models of cholestatic liver disease: A practical guide for translational research.

Authors:  Eva Gijbels; Alanah Pieters; Kevin De Muynck; Mathieu Vinken; Lindsey Devisscher
Journal:  Liver Int       Date:  2021-02-23       Impact factor: 5.828

7.  Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury.

Authors:  Lindsey Devisscher; Mathieu Vinken; Eva Gijbels; Vânia Vilas-Boas; Pieter Annaert; Tamara Vanhaecke
Journal:  Arch Toxicol       Date:  2020-03-10       Impact factor: 5.153

8.  Biliary diseases in heart transplanted patients: a comparison between cyclosporine A versus tacrolimus-based immunosuppression.

Authors:  J Stief; H U Stempfle; M Götzberger; P Uberfuhr; M Köpple; P Lehnert; C Kaiser; Uwe Schiemann
Journal:  Eur J Med Res       Date:  2009-05-14       Impact factor: 2.175

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.